UB Paderborn / Katalog / Suche / in CDI

Guidelines for the management of hemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-01, Vol.19 (1), p.e1-e47

2013

Volltextzugriff (PDF)

Defining extended half‐life rFVIII—A critical review of the evidence

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.348-358

2018

Volltextzugriff (PDF)

Extended half-life clotting factor concentrates: results from published clinical trials

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (S5), p.25-30

2016

Volltextzugriff (PDF)

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Journal of thrombosis and haemostasis, 2015-05, Vol.13 (5), p.743-754

2015

Volltextzugriff (PDF)

Emerging therapies for haemophilia ‐ Global perspective

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (S6), p.15-21

2018

Volltextzugriff (PDF)

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

Journal of thrombosis and haemostasis, 2015-06, Vol.13 (6), p.967-977

2015

Volltextzugriff (PDF)

Deep-vein thrombosis in the era of high HIV and tuberculosis prevalence : a prospective review of its diagnosis and treatment in a quaternary centre

SAMJ: South African Medical Journal, 2017-10, Vol.107 (10), p.859-863

2017

Volltextzugriff (PDF)

TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-11, Vol.22 (6), p.873-879

2016

Volltextzugriff (PDF)

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-01, Vol.24 (1), p.77-84

2018

Volltextzugriff (PDF)

Gene and cell therapy in South Africa : current status and future prospects

South African medical journal, 2019-09, Vol.109 (8 Supplement 1), p.S13-S17

2019

Volltextzugriff (PDF)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Journal of thrombosis and haemostasis, 2014-08, Vol.12 (8), p.1244-1253

2014

Volltextzugriff (PDF)

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.72-80

2016

Volltextzugriff (PDF)

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.1989-1998

2015

Volltextzugriff (PDF)

Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-11, Vol.22 (6), p.912-918

2016

Volltextzugriff (PDF)

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

Journal of thrombosis and haemostasis, 2014-11, Vol.12 (11), p.1788-1800

2014

Volltextzugriff (PDF)

The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH

Journal of thrombosis and haemostasis, 2018-10, Vol.16 (10), p.2106-2110

2018

Volltextzugriff (PDF)

Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-11, Vol.22 (6), p.866-872

2016

Volltextzugriff (PDF)

Dental management of patients with inherited bleeding disorders: a retrospective study

South African Dental Journal, 2018-09, Vol.73 (8), p.500-506

2018

Volltextzugriff (PDF)

Recombinant B‐domain‐deleted porcine sequence factor VIII (r‐pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-01, Vol.23 (1), p.33-41

2017

Volltextzugriff (PDF)

Patient blood management : a solution for South Africa

SAMJ: South African Medical Journal, 2019-07, Vol.109 (7), p.471-476

2019

Volltextzugriff (PDF)

Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa

Antiviral research, 2016-03, Vol.127, p.90-98

2016

Volltextzugriff (PDF)

Prophylaxis is the new standard of care in patients with haemophilia

SAMJ: South African Medical Journal, 2022-06, Vol.112 (6), p.405-408

2022

Volltextzugriff (PDF)

Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor VIII

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.376-384

2018

Volltextzugriff (PDF)

Home therapy for inherited bleeding disorders in South Africa : results of a modified Delphi consensus process

SAMJ: South African Medical Journal, 2019-09, Vol.109 (9), p.639-644

2019

Volltextzugriff (PDF)

Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glycoPEGylated factor IX

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-01, Vol.23 (1), p.67-76

2017

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Guidelines for the management of hemophilia

Defining extended half‐life rFVIII—A critical review of the evidence

Extended half-life clotting factor concentrates: results from published clinical trials

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Emerging therapies for haemophilia ‐ Global perspective

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

Deep-vein thrombosis in the era of high HIV and tuberculosis prevalence : a prospective review of its diagnosis and treatment in a quaternary centre

TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

Gene and cell therapy in South Africa : current status and future prospects

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH

Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies

Dental management of patients with inherited bleeding disorders: a retrospective study

Recombinant B‐domain‐deleted porcine sequence factor VIII (r‐pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors

Patient blood management : a solution for South Africa

Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa

Prophylaxis is the new standard of care in patients with haemophilia

Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor VIII

Home therapy for inherited bleeding disorders in South Africa : results of a modified Delphi consensus process

Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glycoPEGylated factor IX

Suchergebnisse filtern